Immunotech Biopharm

Immunotech Biopharm is the earliest professionally established cellular immunotherapy enterprise registered in China. Founded in November 2016, it has witnessed and actively participated in the entire process of the development of China’s cellular immunotherapy industry from its inception. Immunotech Biopharm focuses on innovative drugs in the field of cellular immunotherapy and has established all the technical platforms required for the research and development of cellular immunotherapy products. Its product portfolio covers a full range of tumor cellular immunotherapy products, including non-genetically modified cells, genetically modified cells, multi-target tumor therapy cells, and single-target tumor therapy cells. The indications cover both solid tumors and hematologic malignancies, forming a tiered pipeline of new products. As an innovative high-tech enterprise specializing in the R&D and application of cellular immunotherapy technologies, it was the first company to obtain clinical trial approval from the China Food and Drug Administration (CFDA) for therapeutic immune cell-based biological products. The company focuses on high-growth niche markets. Compared with its peers, its products offer lower costs and broader applicability. It has obtained clinical trial approvals for two adoptive cellular immunotherapy products.